Tempus AI Rebounds with New AI-Driven Healthcare Initiatives Amid Short Seller Allegations

Tempus AI Stock Is Surging Today: What Investors Are Watching - Tempus AI (NASDAQ:TEM)

Tempus AI Inc TEM shares are moving higher Monday after the company introduced a new program to monitor immunotherapy response for patients with advanced cancer. What Happened: Tempus has announced xM for treatment response monitoring, which is a liquid biopsy assay aimed at detecting molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. The new array for monitoring immunotherapy response is currently only available for research use, but clinical availability is expected later this year. xM for treatment response monitoring is designed to quantify changes in circulating tumor DNA longitudinally from a blood sample by leveraging a multi-parametric algorithm. The company will present new data on xM for treatment response monitoring at the 2025 American Society of Clinical Oncology annual meeting. "We're excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies," said Halla Nimeiri, chief development officer at Tempus AI. "With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies." How To Buy TEM Stock Besides going to a brokerage platform to purchase a share - or fractional share - of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in Tempus AI's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. TEM Price Action: Tempus AI shares were up 17.4% at $64.80 at the time of publication Monday, according to Benzinga Pro. Read Next: Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value Photo: Piotr Swat/Shutterstock. TEMTempus AI Inc$64.5016.9%Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock - anytime. Reveal Full ScoreEdge RankingsMomentumNot AvailableGrowthNot AvailableQualityNot AvailableValue14.79Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Why Shares of Tempus AI Are Jumping Higher This Week | The Motley Fool

Rebounding from their 11.8% decline last week, shares of Tempus AI (TEM 6.12%) are starting June on an auspicious note. In addition to the company dropping two announcements over last weekend, investors responded to TD Cowen commentary addressing Spruce Point's recently released critical report of the company that's specializing in artificial intelligence (AI) solutions for the healthcare industry. According to data provided by S&P Global Market Intelligence, shares of Tempus AI have risen 12% from the end of trading last Friday through 11:37 a.m. ET this morning. "Not much to see here folks. Move along." In essence, that was the response to Spruce Point's critical report on Tempus AI that TD Cowen provided on Monday. According to The Fly, analysts at TD Cowen acknowledged that many of the issues that Spruce Point raised were already known and others were exaggerated -- though it did claim that there were some issues worth further investigation. Along with the commentary regarding the critical report, TD Cowen remained unchanged with its buy rating on Tempus AI stock and $62 price target. In addition to raising doubts about Tempus AI's financial reporting, the critical report that Spruce Point issued last week questioned the nature of the company's collaboration with AstraZeneca. While it's certainly an encouraging sign for current shareholders to see that TD Cowen is unmoved in its opinion despite Spruce Point's report, prospective investors may want to keep their distance for the time being. Investors will likely have to wait until August for the second-quarter 2025 financial results, but in the meantime, those eager to buy shares may want to see if there are additional developments before adding a position.

Why Tempus AI Stock Soared 15% Today | The Motley Fool

Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report last week alleging, among other things, that Tempus is overstating its use of AI. On Friday and Saturday, the company made announcements regarding two AI-driven programs. Whether the timing was deliberate or not, the announcements appeared to help quell doubts introduced by the short seller allegations. Tempus One, the company's AI platform that is intended to help physicians make better decisions, got a key update. The company announced Saturday that the platform will now have direct access to electronic health records (EHR) systems. As the company describes it, the expanded access to data allows the platform to "capture real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams." On Friday, the company announced an initiative it calls Fuses. The company says it will use its vast amount of clinical data to create "an AI-enabled diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality." Today, investors were also pleased to see that TD Cowen is maintaining its buy rating, unconvinced by the short seller's allegations. Despite this, and the company's recent announcements, I believe that Tempus' stock is currently overvalued even if the short seller's allegations don't hold up.